Rheumatic Fever Market Research Report – Forecast to 2027

Rheumatic Fever Market Research Report: By Diagnosis (Physical Exam, Blood Test, Electrocardiogram, Other), by Treatment (Pharmacotherapy), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), by End-User- Forecast Till 2027

ID: MRFR/Pharma/4849-HCR | | Region: Global | 100 pages

Rheumatic Fever Market Scenario


The rheumatic fever market is expected to grow significantly over the forecast period. Rheumatic fever is an autoimmune inflammatory disease which can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves. The increasing occurrences of strep throat and growing prevalence of rheumatic heart disease are expected to be the major drivers for the growth of the market during the forecast period. Moreover, increasing government expenditure for the healthcare sector contributes to the market growth. According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally.


Despite the drivers, lack of awareness about the condition and limited healthcare facilities in emerging economies may hamper the growth of the market during the assessment period.


Segmentation


The global rheumatic fever market has been segmented into diagnosis, treatment, distribution channel, and end-user.


The market on the basis of diagnosis has been segmented into physical exam, blood test, electrocardiogram, and echocardiogram.


The market, by treatment, has been segmented into pharmacotherapy and others. The pharmacotherapy segment is further segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. Further, the anti-inflammatory medication segment has been segmented into aspirin, naproxen, and others.


The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.


On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rheumatic fever market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European rheumatic fever market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The rheumatic fever market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rheumatic fever market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Pfizer, Inc., AstraZeneca, Valeant Pharmaceuticals International, Inc., and Eli Lily and Company are some of the key players in the global rheumatic fever market.


Regional Market Summary


Global Rheumatic Fever Market Share (%), by Region, 2017


 


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the global rheumatic fever market owing to a well-developed healthcare sector, rising prevalence of cardiovascular diseases, and growing healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart diseases in the US every year. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.


Europe is expected to hold the second largest position in the global rheumatic fever market. The market growth in this region is attributed to the growing prevalence of rheumatic heart disease, availability of funds for research, and increasing healthcare expenditure.


Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rheumatic fever, and increasing government funding for the healthcare sector.


On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growing government initiatives for rheumatic heart disease. For instance, according to the RHD Global Status Report, 2015 to 2017, Egypt’s Rheumatic Heart Disease (RHD) programme trained 300 cardiologists and 1,500 primary healthcare physicians in rheumatic heart disease management in 2015. However, the market in the African region is expected to propel owing to the rising prevalence of rheumatic heart disease and increasing government initiatives for the prevention of rheumatic fever.


Global Rheumatic Fever Market, by Diagnosis



  • Physical Exam

  • Blood Test

  • Electrocardiogram

  • Echocardiogram


Global Rheumatic Fever Market, by Treatment



  • Pharmacotherapy

  • Antibiotics

  • Anti-inflammatory Medication

  • Aspirin

  • Naproxen

  • Others

  • Anticonvulsant Medication

  • Others

  • Others


Global Rheumatic Fever Market, by Distribution Channel



  • Retail Pharmacies

  • Hospital Pharmacies

  • Others


Global Rheumatic Fever Market, by End-User



  • Hospitals and Clinics

  • Diagnostic Centers

  • Others


Global Rheumatic Fever Market, by Region



  • Americas



  • North America

  • US

  • Canada

  • South America



  • Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe



  • Asia-Pacific



  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific



  • Middle East & Africa



  • Middle East

  • Africa


Global Rheumatic Fever Market, by Key Players



  • Bayer AG

  • Abbott Laboratories

  • Johnson & Johnson Services, Inc.

  • Hoffmann-La Roche Ltd.

  • Novartis AG

  • Pfizer, Inc.

  • AstraZeneca

  • Valeant Pharmaceuticals International, Inc.

  • Eli Lily and Company

  • Bristol-Myers Squibb Company


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2019-2027:Substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment, Distribution Channel, And End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., F. Hoffman-La Roche Ltd., Novartis AG, Pfizer, Inc., AstraZeneca, Valeant Pharmaceuticals International, Inc., and Eli Lily and Company
  Key Market Opportunities

  • Increasing occurrences of strep throat
  • Growing prevalence of rheumatic heart disease
  •   Key Market Drivers

  • Increasing occurrences of strep throat
  • growing prevalence of rheumatic heart disease


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Lack of awareness and infrastructural problems in the healthcare sector can hold back rheumatic fever market report.

    The diagnosis types included in rheumatic fever market report are electrocardiogram, blood test, physical exam, and echocardiogram.

    Distribution channels included in rheumatic fever market report are hospital pharmacies, retail pharmacies, and others.

    The Americas would display its dominance over global rheumatic fever market.

    The end users included in rheumatic fever market are diagnostic centers, hospitals & clinics, and others.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Rheumatic Fever Market, by Diagnosis

    6.1 Introduction

    6.2 Physical Exam

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.3 Blood Test

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.4 Electrocardiogram (ECG)

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    6.5 Echocardiogram

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    Chapter 7. Global Rheumatic Fever Market, by Treatment

    7.1 Introduction

    7.2 Pharmacotherapy

    7.2.1 Antibiotics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.2 Anti-Inflammatory Medication

    7.2.2.1 Aspirin

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.2.2 Naproxen

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.2.3 Others

    7.2.3 Anticonvulsant Medication

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    7.2.4 Others

    7.3 Others

    Chapter 8. Global Rheumatic Fever Market, by Distribution Channel

    8.1 Introduction

    8.2 Retail Pharmacies

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.3 Hospital Pharmacies

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    8.4 Others

    Chapter 9. Global Rheumatic Fever Market, by End-User

    9.1 Introduction

    9.2 Hospital and Clinics

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.3 Diagnostic Centers

    Market Estimates & Forecast, by Region, 2020–2027

    Market Estimates & Forecast, by Country, 2020–2027

    9.4 Others

    Chapter 10. Global Rheumatic Fever Market, by Region

    10.1 Introduction

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    Chapter 12. Company Profiles

    12.1 Bayer AG

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Abbott Laboratories

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Johnson & Johnson Services, Inc.

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 F. Hoffmann-La Roche Ltd.

    12.4.1 Company Overview

    12.4.2 Product Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Novartis AG

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Pfizer, Inc.

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Bristol-Myers Squibb Company

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 AstraZeneca

    12.8.1 Overview

    12.8.2 Product Overview

    12.8.3 Financials

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Valeant Pharmaceuticals International, Inc.

    12.9.1 Overview

    12.9.2 Product Overview

    12.9.3 Financials

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Eli Lily and Company

    12.10.1 Overview

    12.10.2 Product Overview

    12.10.3 Financials

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s Viewpoint

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Predictions for the Rheumatic Fever Industry

    Chapter 14. Appendix

    LIST OF TABLES

    Table 1 Global Rheumatic Fever Market Synopsis, 2020–2027

    Table 2 Global Rheumatic Fever Market Estimates and Forecast, 2020–2027 (USD Million)

    Table 3 Global Rheumatic Fever Market, by Region, 2020–2027 (USD Million)

    Table 4 Global Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 5 Global Rheumatic Fever Market, by Treatment, 2020–2027(USD Million)

    Table 6 Global Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 7 Global Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 8 North America: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 9 North America: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 10 North America: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD

    Million)

    Table 11 North America: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 12 US: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 13 US: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 14 US: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 15 US: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 16 Canada: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 17 Canada: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 18 Canada: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 19 Canada: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 20 South America: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 21 South America: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 22 South America: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD

    Million)

    Table 23 South America: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 24 Europe: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 25 Europe: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 26 Europe: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 27 Europe: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 28 Western Europe: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 29 Western Europe: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 30 Western Europe: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD

    Million)

    Table 31 Western Europe: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 32 Eastern Europe: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 33 Eastern Europe: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 34 Eastern Europe: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD

    Million)

    Table 35 Eastern Europe: Rheumatic Fever Market, by End-User, 2020–2027(USD Million)

    Table 36 Asia-Pacific: Rheumatic Fever Market, by Diagnosis, 2020–2027 (USD Million)

    Table 37 Asia-Pacific: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 38 Asia-Pacific: Rheumatic Fever Market, by Distribution Channel, 2020–2027 (USD Million)

    Table 39 Asia-Pacific: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    Table 40 Middle East & Africa: Rheumatic Fever Market, by Diagnosis, 2020–2027

    (USD Million)

    Table 41 Middle East & Africa: Rheumatic Fever Market, by Treatment, 2020–2027 (USD Million)

    Table 42 Middle East & Africa: Rheumatic Fever Market, by Distribution Channel, 2020–2027

    (USD Million)

    Table 43 Middle East & Africa: Rheumatic Fever Market, by End-User, 2020–2027 (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Rheumatic Fever Market

    Figure 3 Segmentation Market Dynamics for Global Rheumatic Fever Market

    Figure 4 Global Rheumatic Fever Market Share, by Diagnosis, 2020

    Figure 5 Global Rheumatic Fever Market Share, by Treatment, 2020

    Figure 6 Global Rheumatic Fever Market Share, by Distribution Channel, 2020

    Figure 7 Global Rheumatic Fever Market Share, by End-User, 2020

    Figure 8 Global Rheumatic Fever Market Share, by Region, 2020

    Figure 9 North America: Rheumatic Fever Market Share, by Country, 2020

    Figure 10 Europe: Rheumatic Fever Market Share, by Country, 2020

    Figure 11 Asia-Pacific: Rheumatic Fever Market Share, by Country, 2020

    Figure 12 Middle East & Africa: Rheumatic Fever Market Share, by Country, 2020

    Figure 13 Global Rheumatic Fever Market: Company Share Analysis, 2020 (%)

    Figure 14 Bayer AG: Key Financials

    Figure 15 Bayer AG: Segmental Revenue

    Figure 16 Bayer AG: Geographical Revenue

    Figure 17 Abbott Laboratories: Key Financials

    Figure 18 Abbott Laboratories: Segmental Revenue

    Figure 19 Abbott Laboratories: Geographical Revenue

    Figure 20 Johnson & Johnson Services, Inc.: Key Financials

    Figure 21 Johnson & Johnson Services, Inc.: Segmental Revenue

    Figure 22 Johnson & Johnson Services, Inc.: Geographical Revenue

    Figure 23 F. Hoffmann-La Roche Ltd.: Key Financials

    Figure 24 F. Hoffmann-La Roche Ltd.: Segmental Revenue

    Figure 25 F. Hoffmann-La Roche Ltd.: Geographical Revenue

    Figure 26 Novartis AG: Key Financials

    Figure 27 Novartis AG: Segmental Revenue

    Figure 28 Novartis AG. Geographical Revenue

    Figure 29 Pfizer, Inc.: Key Financials

    Figure 30 Pfizer, Inc.: Segmental Revenue

    Figure 31 Pfizer, Inc.: Geographical Revenue

    Figure 32 Bristol-Myers Squibb Company: Key Financials

    Figure 33 Bristol-Myers Squibb Company: Segmental Revenue

    Figure 34 Bristol-Myers Squibb Company: Geographical Revenue

    Figure 35 AstraZeneca: Key Financials

    Figure 36 AstraZeneca: Segmental Revenue

    Figure 37 AstraZeneca: Geographical Revenue

    Figure 38 Valeant Pharmaceuticals International, Inc.: Key Financials

    Figure 39 Valeant Pharmaceuticals International, Inc.: Segmental Revenue

    Figure 40 Valeant Pharmaceuticals International, Inc.: Geographical Revenue

    Figure 41 Eli Lily and Company: Key Financials

    Figure 42 Eli Lily and Company: Segmental Revenue

    Figure 43 Eli Lily and Company: Geographical Revenue